Mirai Medical raises $8.4M to support PFA tech
Mirai Medical announced that it secured approximately $8.4 million (€7.2 million) in funding from the Irish government. The Galway-based company earned its funding through the country’s Disruptive Technologies Innovation Fund (DTIF) Call 7 for its PIONEER technology — Pathology and Immuno-Oncology with Next-Generation Screening and Electroporation for Enhanced Response. Read More
OncoAssure Announces Collaboration with Leading US Medical Centre for Prostate Cancer Test Validation Study
OncoAssure, an Irish medtech company and a leading innovator in precision oncology diagnostics, today announced the signing of a research collaboration agreement with the Icahn School of Medicine at Mount Sinai, in New York, which will facilitate the performance of a new validation study utilising OncoAssure’s Prostate Cancer Test and curated clinical samples from Icahn School of Medicine at Mount Sinai. Read More
FDA Approves the ProVee System – the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH
FDA Approves the ProVee System - the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH. ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it has received FDA approval for its ProVee® System for BPH. FDA approval was supported by results from the ProVIDE study, a randomized, double-blind, sham-controlled trial evaluating the safety [...]
Deciphex Secures €15M Venture Debt Funding from Claret Capital Partners to Accelerate Growth
Deciphex, a leader in AI-powered digital pathology, today announced the execution of a new €15 million investment from Claret Capital Partners, Europe's largest independent growth debt fund manager. This strategic financing will accelerate Deciphex's expansion in the United States and support the company's ambition to become the leading provider of histopathology reporting services in the UK by 2027. Read More
OncoAssure launches next-generation prostate test in the US
NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year. The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence. Read More
Cinclus Pharma Partners with Zentiva to Commercialize Linaprazan Glurate in Europe
Cinclus Pharma Holding, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases, has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe. Read More
Signum Surgical is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer.
Signum Surgical, the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. Ms. Burns’ appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide. Read More [...]
Aruna’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, Inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the Company’s Co-Founder and Chief Scientific Officer, Dr. Steven Stice, has been inducted into the 2025 Class of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Read More